Lantheus Holdings to Present at Upcoming Investor Conferences

Rhea-AI Summary

Lantheus (NASDAQ: LNTH) has announced that Mary Anne Heino, President and CEO, and Bob Marshall, CFO and Treasurer, will present at upcoming investor conferences. The presentations will take place at the Wells Fargo 2021 Virtual Healthcare Conference on September 9, 2021, and at the Baird 2021 Global Healthcare Conference on September 15, 2021. Investors can access a live webcast of these presentations via Lantheus's website, with replays available for 30 days post-event.

NORTH BILLERICA, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow serious medical conditions, today announced Mary Anne Heino, President and Chief Executive Officer, and Bob Marshall, Chief Financial Officer and Treasurer, will present at the following investor conferences.

• Wells Fargo 2021 Virtual Healthcare Conference
  September 9, 2021 at 4 p.m. ET
  

• Baird 2021 Global Healthcare Conference
  September 15, 2021 at 7:55 a.m. ET
  

To access a live webcast of the presentation, please visit the Investors section of the Company’s website at www.lantheus.com. A replay of the webcast will be available on the Company’s website for 30 days following the live presentation.

About Lantheus Holdings, Inc.
Lantheus Holdings, Inc. is the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc. and EXINI Diagnostics AB and an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find Fight and Follow^® serious medical conditions. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY^® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY^®, a PSMA PET imaging agent for the detection of suspected recurrent or metastatic prostate cancer; TechneLite^® (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; AZEDRA^® for the treatment of certain rare neuroendocrine tumors; and RELISTOR^® for the treatment of opioid-induced constipation, which is partnered with Bausch Health Companies, Inc. The Company is headquartered in North Billerica, Massachusetts with offices in New York, New Jersey, Canada and Sweden. For more information, visit www.lantheus.com.

Contacts:
Mark Kinarney
Senior Director, Investor Relations
978-671-8842
ir@lantheus.com

Melissa Downs
Director, Corporate Communications
646-975-2533
media@lantheus.com

FAQ

What events will Lantheus (LNTH) present at in September 2021?

Lantheus will present at the Wells Fargo 2021 Virtual Healthcare Conference on September 9, 2021, and at the Baird 2021 Global Healthcare Conference on September 15, 2021.

Who will represent Lantheus (LNTH) at the investor conferences?

Mary Anne Heino, President and CEO, and Bob Marshall, CFO and Treasurer, will represent Lantheus at the conferences.

How can I access Lantheus's (LNTH) conference presentations?

You can access live webcasts of Lantheus's presentations on their Investors section of the website. Replays will be available for 30 days after the events.

What is Lantheus (LNTH) known for?

Lantheus is known for its innovative imaging diagnostics, targeted therapeutics, and artificial intelligence solutions in the medical field.